SB-743921 hydrochloride (also known as SB743921 HCl or SB743921, CAS: 940929-33-9) is a small molecule inhibitor of checkpoint kinase 1 (Chk1), an enzyme involved in the DNA damage response pathway. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors.
Chemical name: 2-Methoxy-6-(3-(3-morpholinopropylamino)pyrrolidin-1-yl)pyrazine
Molecular formula: C16H28N4O2
Formula weight: 312.42 g/mol
CAS No: 940929-33-9
Top ten keywords from Google:
Synonyms:
Health benefits of this product: SB-743921 hydrochloride has demonstrated potential health benefits in the area of cancer research, particularly in the treatment of solid tumors. Its primary mode of action is through inhibition of Chk1, leading to disrupted DNA damage response and subsequent cell death.
Potential effects: SB-743921 hydrochloride has demonstrated efficacy in several preclinical and clinical studies in inhibiting the activity of Chk1, leading to disrupted DNA damage response and subsequent cell death. It also has potential benefits for inducing apoptosis (programmed cell death), reducing angiogenesis (the formation of new blood vessels that can support tumor growth), and enhancing the immune response to cancer cells. SB-743921 hydrochloride works by disrupting various cellular processes that are necessary for cancer cell survival and growth.
Product mechanism: SB-743921 hydrochloride works by inhibiting the activity of Chk1, which is an enzyme involved in the DNA damage response pathway. By inhibiting Chk1, SB-743921 hydrochloride can disrupt the DNA damage response and subsequent cell death, leading to reduced tumor growth and increased apoptosis.
Safety: SB-743921 hydrochloride has been evaluated in several preclinical and clinical trials involving hundreds of participants and has been generally well-tolerated. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as hematological abnormalities (e.g., decreased white blood cell or platelet counts) and hepatic dysfunction. Patients with liver or kidney disease should exercise caution when taking SB-743921 hydrochloride, as it may affect these conditions. Pregnant or breastfeeding women should avoid using SB-743921 hydrochloride, as its safety in these populations has not been established.
Side effects: Less common but more severe side effects of SB-743921 hydrochloride may include bleeding disorders, cardiovascular events, and liver or kidney dysfunction, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of SB-743921 hydrochloride may vary depending on the patient's condition and treatment goals. In preclinical studies, doses ranging from 0.5 to 10 mg have been evaluated for various types of cancer. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: SB-743921 hydrochloride (SB743921 HCl or SB743921, CAS: 940929-33-9) is a small molecule inhibitor of Chk1, an enzyme involved in the DNA damage response pathway. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors. Although it has been generally well-tolerated in preclinical and clinical trials, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient populations and cancer types. SB-743921 hydrochloride offers a promising avenue for treatment of cancer by disrupting DNA damage response and inducing cell death
